High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation - Full Text View

High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation

This study is currently recruiting participants.
Verified by Alberta Cancer Board, April 2007

Sponsored by:	Alberta Cancer Board
Information provided by:	Alberta Cancer Board
ClinicalTrials.gov Identifier:	NCT00126854

Purpose

The purpose of this study is to establish the correct scanning parameters for obtaining good quality 3 Tesla (3T) magnetic resonance spectroscopy images (MRSI) of the prostate gland before and after brachytherapy implantation for prostate cancer. Three Tesla MRSI may be a valuable additional diagnostic and follow-up investigation for prostate cancer patients.

Condition	Intervention
Prostatic Neoplasm	Procedure: Magnetic Resonance Spectroscopy Imaging

MedlinePlus related topics:

Cancer Prostate Cancer

ChemIDplus related topics:

Iodine Cadexomer iodine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Official Title:	High Field (3 Tesla) Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Permanent Iodine 125 Brachytherapy Implantation

Further study details as provided by Alberta Cancer Board:

Primary Outcome Measures:

pilot study meant to establish scanning parameters on 3T MRSI

Secondary Outcome Measures:

safety/toxicity

Estimated Enrollment:	10
Study Start Date:	October 2005
Estimated Study Completion Date:	November 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Suitable candidate for prostate brachytherapy to treat prostate cancer
Patient signs a study consent form

Exclusion Criteria:

Have received other radiotherapy for prostate cancer or hormone treatments
Has contraindication to MRSI scanning
Does not sign study consent form

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00126854

Contacts


Contact: Don Yee, MD	780-432-8749	donyee@cancerboard.ab.ca

Locations


Canada, Alberta
	Cross Cancer Institute	Recruiting
	Edmonton, Alberta, Canada, T6G 1Z2
	Contact: Paula Langenhoff 780-432-8909 paulalan@cancerboard.ab.ca
	Principal Investigator: Don Yee, MD

Sponsors and Collaborators

Alberta Cancer Board

Investigators


Principal Investigator:	Don Yee, MD	Alberta Cancer Board

More Information

Study ID Numbers:	NA-15-0003
First Received:	August 3, 2005
Last Updated:	April 10, 2007
ClinicalTrials.gov Identifier:	NCT00126854
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Cancer Board:

brachytherapy

magnetic resonance spectroscopy

Study placed in the following topic categories:

Prostatic Diseases

Genital Neoplasms, Male

Iodine

Urogenital Neoplasms

Genital Diseases, Male

Prostatic Neoplasms

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

ClinicalTrials.gov processed this record on August 28, 2008